Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

医学 间变性淋巴瘤激酶 临床终点 碱性抑制剂 克里唑蒂尼 ROS1型 人口 酪氨酸激酶抑制剂 肺癌 内科学 铈替尼 肿瘤科 临床试验 癌症 腺癌 环境卫生 恶性胸腔积液
作者
Alice Tsang Shaw,Enriqueta Felip,Todd Michael Bauer,Benjamin Besse,Alejandro Navarro,Sophie C. Postel-Vinay,Justin F. Gainor,Melissa Lynne Johnson,Jörg Dietrich,Leonard Philip James,Jill S. Clancy,Joseph Chen,Jean‐François Martini,Antonello Abbattista,Benjamin Solomon
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (12): 1590-1599 被引量:659
标识
DOI:10.1016/s1470-2045(17)30680-0
摘要

Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS. This study aimed to analyse the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclinical activity against most known resistance mutations, in patients with advanced ALK-positive or ROS1-positive NSCLC.In this international multicentre, open-label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-positive or ROS1-positive NSCLC and were older than 18 years, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate end-organ function. Lorlatinib was administered orally to patients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a minimum of three patients receiving each dose. For some patients, tumour biopsy was done before lorlatinib treatment to identify ALK resistance mutations. Safety was assessed in patients who received at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment and had either ALK or ROS1 rearrangement). The primary endpoint was dose-limiting toxicities during cycle 1 according to investigator assessment; secondary endpoints included safety, pharmacokinetics, and overall response. This study is ongoing and is registered with ClinicalTrials.gov, number NCT01970865.Between Jan 22, 2014, and July 10, 2015, 54 patients received at least one dose of lorlatinib, including 41 (77%) with ALK-positive and 12 (23%) with ROS1-positive NSCLC; one patient had unconfirmed ALK and ROS1 status. 28 (52%) patients had received two or more TKIs, and 39 (72%) patients had CNS metastases. The most common treatment-related adverse events among the 54 patients were hypercholesterolaemia (39 [72%] of 54 patients), hypertriglyceridaemia (21 [39%] of 54 patients), peripheral neuropathy (21 [39%] of 54 patients), and peripheral oedema (21 [39%] of 54 patients). One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributable to study drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation and word-finding difficulty). No maximum tolerated dose was identified. The recommended phase 2 dose was selected as 100 mg once daily. For ALK-positive patients, the proportion of patients who achieved an objective response was 19 (46%) of 41 patients (95% CI 31-63); for those who had received two or more TKIs, the proportion of patients with an objective response was 11 (42%) of 26 patients (23-63). In ROS1-positive patients, including seven crizotinib-pretreated patients, an objective response was achieved by six (50%) of 12 patients (95% CI 21-79).In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail. Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-positive NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomised controlled trial comparing lorlatinib to crizotinib (ClinicalTrials.gov, NCT03052608).Pfizer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shimhjy完成签到,获得积分10
1秒前
莓莓发布了新的文献求助10
3秒前
陈杰77完成签到,获得积分20
4秒前
在水一方的应助被Suifqh采纳,获得10
4秒前
研友_8Y2DXL完成签到,获得积分10
5秒前
sun完成签到,获得积分10
5秒前
老实人sdu发布了新的文献求助10
5秒前
羲成完成签到,获得积分10
7秒前
慕青的应助被哈哈哈采纳,获得10
7秒前
7秒前
小二郎的应助被moriaty采纳,获得10
9秒前
火星上的海亦完成签到,获得积分10
10秒前
我是老大的应助被洁净的千凡采纳,获得10
10秒前
小木没有烦恼完成签到 ,获得积分10
10秒前
理穆辛完成签到 ,获得积分10
10秒前
11秒前
外向夜春完成签到 ,获得积分10
12秒前
小艾同学发布了新的文献求助10
12秒前
Roux给Roux的求助进行了留言
13秒前
善良的采蓝的应助被土豪的城采纳,获得30
13秒前
hhh发布了新的文献求助10
15秒前
Davin_ji完成签到 ,获得积分10
15秒前
星辰大海的应助被wwwwwl采纳,获得10
16秒前
16秒前
17秒前
17秒前
18秒前
椰子鸡完成签到 ,获得积分10
18秒前
18秒前
18秒前
Charles完成签到,获得积分10
19秒前
19秒前
19秒前
fantasy的应助被隔岸采纳,获得10
19秒前
芽卉完成签到 ,获得积分10
20秒前
爆米花的应助被鼻毛好胜采纳,获得10
20秒前
乐乐的应助被111采纳,获得10
21秒前
WZJ发布了新的文献求助30
21秒前
chaoqi完成签到,获得积分10
22秒前
CipherSage的应助被Leonard采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552